| Japanese |
|---|
| Title | 131I標識抗CA19-9および抗CEAモノクローナル抗体によるimmunoscintigraphyの基礎的検討 - IMACIS-1による担癌マウスのイメージングおよびヒト癌細胞のcell ELISA - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 野上俊彦*, 三浦博*, 近江昭一*, 風早康弘* |
|---|
| Authors(kana) | |
|---|
| Organization | *シーアイエスダイアグノスティック株式会社研究開発部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 27 |
|---|
| Number | 5 |
|---|
| Page | 427-436 |
|---|
| Year/Month | 1990/5 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」 131I標識されたヒト癌関連抗原に対する2種類のマウスモノクローナル抗体, 抗CA19-9抗体, 抗CEA抗体のカクテル製剤 (IMACIS-1) を用いたradioimmunoimagingの有用性を担癌ヌードマウスを用いて比較検討した. マウスに移植されたヒト癌株細胞 (SW 948, COLO 201) は, IMACIS-1投与後48〜72時間で腫瘍の描出が明瞭となった. COLO 201での腫瘍 / 血液比は投与後72時間で8.69, SW 948で5.70であり, 他のヒト癌株細胞であるPC-3, HEp-2のそれと比較して約10〜15倍の高い値が得られた. IMACIS-1は, 腫瘍のイメージング剤として有用であると考えられた. またin vitroでcell ELISAを行った結果, 両細胞ともに抗CA19-9抗体と特異的に反応し, 抗CEA抗体とは反応しなかった. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | IMACIS-1, Monoclonal antibodies, Radioimmunoscintigram, CA19-9, Cell ELISA |
|---|
| English |
|---|
| Title | A Fundamental Study of Immunoscintigraphy with 131I-labeled Anti-CA19-9 and Anti-CEA Monoclonal Antibodies - Imaging of Tumor-Bearing Mice by IMACIS-1 and Cell ELISA with Human Tumor Cells - |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Toshihiko NOGAMI, Hiroshi MIURA, Shoichi OHMI, Yasuhiro KAZAHAYA |
|---|
| Authors(kana) | |
|---|
| Organization | Product License Department, CIS DIAGNOSTIC K. K. |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 27 |
|---|
| Number | 5 |
|---|
| Page | 427-436 |
|---|
| Year/Month | 1990/5 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] A study was made on 2 types of 131I-labeled anti-CA19-9 and anti-CEA mouse monoclonal antibodies (IMACIS-1) against human cancer related antigen as to their usefulness in radioimmunoimaging. Tumor-bearing nude mice were used for comparison. The transplanted tumors (SW 948, COLO 201) were clearly visualized 48-72 hours after administration of IMACIS-1. Tumor/blood ratio 72 hours after administration : 8.69 in COLO 201 and 5.70 in SW 948, showing ca. 10-15 times as high as those in PC-3 and HEp-2. IMACIS-1 therefore is considered useful in radioimmunoimaging of cancer. Analysis was made by in vitro cell ELISA. As a result, both of the cells specifically reacted with anti-CA19-9 but not anti-CEA. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | IMACIS-1, Monoclonal antibodies, Radioimmunoscintigram, CA19-9, Cell ELISA |
|---|